stockrow
Friday 6 November 2026
Export PCRX’s income statement to Excel — free account
Pacira BioSciences, Inc.
PCRX Healthcare Drug Manufacturers Specialty & Generic
Pacira BioSciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $726.4 million, up 3.63% from fiscal 2024.
- Revenue
- −1.59%
- EPS
- +500.0%
- Free cash flow
- −18.5%
- Total debt
- −37.4%
Quarter to September 2026, against a year earlier
36.44
0.04
+0.11%
Follow PCRX
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
| 5.24% | 2.05% | 0.71% | 0.96% |
+8 more TTM periods Free account |
|
Piotroski F-Score |
— | 8 | 8 | 8 | |
| 3.02% | 1.05% | 0.37% | 0.50% | ||
ROIC |
5.37% | 1.58% | 1.84% | 1.45% | |
Return on Tangible Assets |
6.36% | 2.35% | 0.95% | 1.24% | |
Average Days of Receivables |
60.35 | 64.78 | 62.40 | 62.34 | |
Free Cash Flow per Share |
4.24 | 4.55 | 3.28 | 3.07 | |
Free Cash Flow |
169.00 | 179.52 | 132.71 | 136.66 | |
Capital Expenditures |
(7.90) | (8.15) | (9.51) | (15.33) | |
| Other line items | |||||
Cash ROIC |
16.77% | 13.96% | 10.84% | 10.48% | |
Accounts Receivable Turnover |
6.24 | 6.05 | 6.38 | 6.12 | |
Accounts Payable Turnover |
0.00 | 6.51 | 8.17 | 8.74 | |
Inventory Turnover |
0.00 | 1.10 | 1.07 | 1.08 | |
Average Days of Payables |
0.00 | 41.19 | 33.68 | 36.93 | |
Days of Inventory on Hand |
0.00 | 316.59 | 361.43 | 372.59 | |
Tax Rate |
0.02 | (0.17) | (0.61) | (0.58) | |
Research and Development Expense of Revenue |
16.52% | 16.36% | 16.34% | 16.15% | |
Selling, General and Administrative Expense of Revenue |
49.94% | 50.81% | 51.16% | 50.76% | |
Share Based Compensation of Revenue |
7.24% | 7.50% | 7.69% | 7.92% | |
Interest Coverage |
2.54 | 1.28 | 1.46 | 1.10 | |
Operating CF/Net income |
4.69 | 12.82 | 27.68 | 21.61 | |
Depreciation/Fixed assets |
0.00 | 0.64 | 0.66 | 0.63 | |
Capex/Depreciation |
0.00 | (0.10) | (0.11) | (0.17) | |
Revenue per Share |
18.65 | 18.91 | 18.16 | 16.30 | |
Operating CF per Share |
4.44 | 4.76 | 3.51 | 3.41 | |
Capex per Share |
(0.20) | (0.21) | (0.23) | (0.34) | |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.02 |
Columns are period end dates · fundamentals updated 5 Nov 2026